Skip to main content Skip to search Skip to main navigation

EU: Revised Device Surveillance Guidance

The Medical Device Coordination Group (MDCG) issued a second revision to its surveillance guidance for medical devices. The changes align the guidance with EU regulations on transitional provisions for certain medical devices and in vitro diagnostic devices (IVDs).

The document addresses the transition periods according to Article 120 of the Medical Device Regulation (MDR), covering devices certified under the old Medical Devices Directive (MDD) or the Active Implantable Medical Devices Directive (AIMDD). For all class III devices, and for certain class IIb implantable devices the transition period ends on 31 December 2027. For class IIb devices other than those covered by the previous point, for class IIa devices, and for class I devices placed on the market in sterile condition or having a measuring function the transition period ends on 31 December 2028.

The guidance specifies that appropriate surveillance applies only to "legacy devices" with MDD or AIMDD certificates. Devices not requiring a notified body under MDD are exempt from surveillance under Article 120, even if MDR requires it.

If the notified body that issued the MDD or AIMDD certificate is not MDR-designated, surveillance responsibility ends on 25 September 2024. After this date, the responsibility shifts to the notified body with which the manufacturer has an MDR certification agreement.


Source:

MDCG 2022-4 Rev 2, Guidance on appropriate surveillance regarding the transitional provisions under Article 120 of the MDR with regard to devices covered by certificates according to the MDD or the AIMDD

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

EU: Agreement on the Pharmaceutical Package

EU: Agreement on the Pharmaceutical Package

On 11 December, the European Commission, the European Parliament, and the Council of the European Union reached a provisional agreement to update Europe's medicinal products regulatory framework.

Read more
EMA: Updated Q&As for Biological Medicinal Products

EMA: Updated Q&As for Biological Medicinal Products

EMA has updated its Q&A on biological medicinal products, addressing topics that previously required clarification or were subject to differing interpretation. The latest revision adds six new questions and updates several existing answers.

Read more
ICH: New Recommendations for the Manufacture of ATMPs

ICH: New Recommendations for the Manufacture of ATMPs

The ICH’s Cell and Gene Therapy Discussion Group (CGTDG), which was established in May 2023, has provided recommendations with regard to future Advanced Therapy Medicinal Products (ATMPs) Related Guidelines.

Read more
GMP Publishing Embarks on a new Digital Chapter

GMP Publishing Embarks on a new Digital Chapter

After months of intensive work, creative ideas, and technical finesse, the time has finally come: the GMP Verlag website has been given a fresh new look.
Read more
 Basics on the Integrity of Container Closure Systems

Basics on the Integrity of Container Closure Systems

The integrity of a primary packaging system (container closure system) is essential to prevent product loss by leakage or evaporation and at the same time protect the product from contamination. The task of a primary packaging system (container closure system) is essentially to prevent the product from being lost (e.g. leakage, evaporation, etc.) and to prevent the product from being contaminated from the outside.

Read more
What should be considered in risk assessment?

What should be considered in risk assessment?

You can view the answer here:
Read more
Previous
Next